相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Accuracy of 99mTc-Hydroxymethylene diphosphonate scintigraphy for diagnosis of transthyretin cardiac amyloidosis
Francesco Cappelli et al.
JOURNAL OF NUCLEAR CARDIOLOGY (2019)
Nuclear imaging of cardiac amyloidosis
Efstathia Andrikopoulou et al.
JOURNAL OF NUCLEAR CARDIOLOGY (2019)
Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone
Nelson Leung et al.
HAEMATOLOGICA (2018)
Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone
Nelson Leung et al.
HAEMATOLOGICA (2018)
Phase 2 trial of daily, oral epigallocatechin gallate in patients with light-chain amyloidosis
Sohsuke Meshitsuka et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2017)
Emerging therapeutic targets currently under investigation for the treatment of systemic amyloidosis
Mario Nuvolone et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2017)
Magnetic Resonance in Transthyretin Cardiac Amyloidosis
Ana Martinez-Naharro et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2017)
Encouraging impact of doxycycline on early mortality in cardiac light chain (AL) amyloidosis
A. D. Wechalekar et al.
BLOOD CANCER JOURNAL (2017)
Targeted Nuclear Imaging Probes for Cardiac Amyloidosis
Paco E. Bravo et al.
CURRENT CARDIOLOGY REPORTS (2017)
Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma
Shaji Kumar et al.
BLOOD (2017)
Promising efficacy and acceptable safety of venetoclax plus bortezomib and dexamethasone in relapsed/refractory MM
Philippe Moreau et al.
BLOOD (2017)
Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis
Gregory P. Kaufman et al.
BLOOD (2017)
A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis
Vaishali Sanchorawala et al.
BLOOD (2017)
Preclinical data support leveraging CS1 chimeric antigen receptor T-cell therapy for systemic light chain amyloidosis
Michael Rosenzweig et al.
CYTOTHERAPY (2017)
A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis
Giovanni Palladini et al.
BLOOD (2017)
Interim analysis of the phase 1a/b study of chimeric fibril-reactive monoclonal antibody 11-1F4 in patients with AL amyloidosis
Camille V. Edwards et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2017)
Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid-directed monoclonal antibody
Morie A. Gertz et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis
Kristopher J. Swiger et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2016)
Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial
Vaishali Sanchorawala et al.
BLOOD (2016)
Varying levels of small microcalcifications and macrophages in ATTR and AL cardiac amyloidosis: implications for utilizing nuclear medicine studies to subtype amyloidosis
Miriam A. Stats et al.
CARDIOVASCULAR PATHOLOGY (2016)
Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis
Julian D. Gillmore et al.
CIRCULATION (2016)
First-in-Human Phase I/II Study of NEOD001 in Patients With Light Chain Amyloidosis and Persistent Organ Dysfunction
Morie A. Gertz et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
P. Moreau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
LGE Provides Incremental Prognostic Information Over Serum Biomarkers in AL Cardiac Amyloidosis
Samuel J. Boynton et al.
JACC-CARDIOVASCULAR IMAGING (2016)
Soluble suppression of tumorigenicity 2 (sST2), but not galactin-3, adds to prognostication in patients with systemic AL amyloidosis independent of NT-proBNP and troponin T
Angela Dispenzieri et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Kinetics of organ response and survival following normalization of the serum free light chain ratio in AL amyloidosis
Gregory P. Kaufman et al.
AMERICAN JOURNAL OF HEMATOLOGY (2015)
Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens
Tilmann Bochtler et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component
Duncan B. Richards et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis
Arnt V. Kristen et al.
AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS (2014)
How to Image Cardiac Amyloidosis
Rodney H. Falk et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2014)
Effect of Combined Systolic and Diastolic Functional Parameter Assessment for Differentiation of Cardiac Amyloidosis From Other Causes of Concentric Left Ventricular Hypertrophy
Dan Liu et al.
CIRCULATION-CARDIOVASCULAR IMAGING (2013)
Revised Prognostic Staging System for Light Chain Amyloidosis Incorporating Cardiac Biomarkers and Serum Free Light Chain Measurements
Shaji Kumar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias
Victor L. Villemagne et al.
JOURNAL OF NUCLEAR MEDICINE (2011)
Radioimmunodetection of amyloid deposits in patients with AL amyloidosis
Jonathan S. Wall et al.
BLOOD (2010)
Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy
E Perugini et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2005)
Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: A staging system for primary systemic amyloidosis
A Dispenzieri et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
分享论文
